1. Clinical & Scientific Overview
Voglibose IP (TIP-MED-000284, Reference Code [4.12]-CMP14) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Alpha-Glucosidase Inhibitor; Intestinal Brush-Border Carbohydrate Digestion Blocker.
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Potent alpha-glucosidase inhibitor (0.2/0.3 mg TDS with first bite of meal) with lower flatulence incidence than Acarbose.
Standard approved strengths (refer to comparative context)
3. Mechanism of Action & Pharmacodynamics
Potent alpha-glucosidase inhibitor (0.2/0.3 mg TDS with first bite of meal) with lower flatulence incidence than Acarbose.
4. Therapeutic Indications & Evidence-Supported Uses
- Type 2 diabetes mellitus targeting elevated postprandial blood glucose (PPBG)—highly suited to high-carbohydrate Indian diets (rice, chapati, idli, poha, potatoes)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Potent alpha-glucosidase inhibitor (0.2/0.3 mg TDS with first bite of meal) with lower flatulence incidence than Acarbose.
Administration & Meal Timing: MUST be chewed with the VERY FIRST BITE of the meal (or swallowed whole immediately with the first mouthful of food)! If taken 30 minutes before or 15 minutes after the meal, it misses the food bolus in the duodenum and fails to work. | With breakfast, lunch, and dinner (depending on prescribed frequency).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Comparative pharmacokinetic profile co-indexed under [4.12].
Renal: Although <2% of active acarbose is absorbed, inactive and active metabolites accumulate in severe CKD—contraindicated if CrCl <25 mL/min. Hepatic: Contraindicated in hepatic cirrhosis; monitor LFTs if high doses are used.
Renal: Although <2% of active acarbose is absorbed, inactive and active metabolites accumulate in severe CKD—contraindicated if CrCl <25 mL/min. Hepatic: Contraindicated in hepatic cirrhosis; monitor LFTs if high doses are used.
Renal: Although <2% of active acarbose is absorbed, inactive and active metabolites accumulate in severe CKD—contraindicated if CrCl <25 mL/min. Hepatic: Contraindicated in hepatic cirrhosis; monitor LFTs if high doses are used.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in inflammatory bowel disease (ulcerative colitis, Crohn's disease), colonic ulceration, partial intestinal obstruction/ileus, chronic malabsorption syndromes, severe hernia (due to intestinal gas distension), cirrhosis, and severe renal impairment (CrCl <25 mL/min).
Key Clinical Precautions: Renal: Although <2% of active acarbose is absorbed, inactive and active metabolites accumulate in severe CKD—contraindicated if CrCl <25 mL/min. Hepatic: Contraindicated in hepatic cirrhosis; monitor LFTs if high doses are used.
8. Adverse Effects Profile
- Flatulence (excess intestinal gas, 30–50%), abdominal distension/meteorism, borborygmi, soft stools/diarrhoea (caused by colonic bacterial fermentation of undigested complex carbohydrates; improves with gradual titration and reducing refined sugar/heavy starch intake; Voglibose causes slightly less flatulence than Acarbose).
- Paralytic ileus / subacute intestinal obstruction, reversible asymptomatic hepatic transaminase elevation (mostly at high doses >150–300 mg/day), pneumatosis cystoides intestinalis (rare).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Digestive enzyme preparations (containing amylase/pancreatin) and charcoal/adsorbents directly cleave carbohydrates or bind acarbose, completely abolishing its efficacy—do not co-administer! Reduces oral bioavailability of digoxin and metformin mildly
- Increases warfarin INR rarely
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [4.12].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Mandatory Hypoglycaemia Rescue Rule (Glucose vs. Table Sugar): While acarbose alone does not cause hypoglycaemia, if the patient is also taking a sulfonylurea (glimepiride) or insulin and develops low blood sugar, ordinary table sugar (sucrose / chini), jaggery, or biscuits will NOT raise blood sugar quickly because acarbose blocks the sucrase enzyme! The patient MUST carry and take pure Glucose powder (Glucon-D / Dextrose tablets), milk, or honey (monosaccharides that do not require sucrase digestion).
- Meal & Clock Timing Instruction: MUST be chewed with the VERY FIRST BITE of the meal (or swallowed whole immediately with the first mouthful of food)! If taken 30 minutes before or 15 minutes after the meal, it misses the food bolus in the duodenum and fails to work. (With breakfast, lunch, and dinner (depending on prescribed frequency).)
- Missed Dose Protocol: CRITICAL RULE: If remembered AFTER finishing the meal, SKIP the missed dose completely! Taking acarbose on an empty stomach after a meal has zero effect because the food has already been digested and absorbed.
- Geriatric Dispensing Pearl: Verify the patient does not have chronic constipation, diverticulitis, or abdominal hernia before starting; counsel to chew with the first bite of roti or rice.
Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [4.18]-C17 Alogliptin — Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Schedule H)
- [4.22]-C18 Dulaglutide — Subcutaneous GLP-1 Receptor Agonists (Schedule H | 2°C–8°C Cold C
- [4.24]-C19 Intravenous Dextrose (25% / 50%) — Hyperglycaemic Glycogenolytic Hormone & Emergency Carbohydrate Re
- [4.24]-C20 Oral Glucose — Hyperglycaemic Glycogenolytic Hormone & Emergency Carbohydrate Re
